ORIGINAL RESEARCH
Published on 06 Oct 2017
Upregulation of HLA Class I Expression on Tumor Cells by the Anti-EGFR Antibody Nimotuzumab
doi 10.3389/fphar.2017.00595
- 8,265 views
- 34 citations
- Frontiers in Pharmacology
- Cancer Molecular Targets and Therapeutics
- Research Topics
- Targeting the ErbB/Her receptor family for cancer therapy: connecting oncogenes with immunity
Targeting the ErbB/Her receptor family for cancer therapy: connecting oncogenes with immunity
10k
Total downloads
44k
Total views and downloads
Articles
REVIEW
Published on 24 Aug 2017
The Immune System's Contribution to the Clinical Efficacy of EGFR Antagonist Treatment
doi 10.3389/fphar.2017.00575
- 6,212 views
- 32 citations
ORIGINAL RESEARCH
Published on 19 Jun 2017
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
doi 10.3389/fphar.2017.00382
- 5,625 views
- 47 citations
MINI REVIEW
Published on 30 May 2017
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
doi 10.3389/fphar.2017.00332
- 5,663 views
- 27 citations
ORIGINAL RESEARCH
Published on 10 May 2017
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial
doi 10.3389/fphar.2017.00263
- 3,670 views
- 19 citations
MINI REVIEW
Published on 26 Oct 2016
Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment
doi 10.3389/fphar.2016.00405
- 7,631 views
- 49 citations
REVIEW
Published on 06 Oct 2016
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention
doi 10.3389/fphar.2016.00356
- 6,891 views
- 36 citations
REVIEW
Published on 26 Sep 2016
Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model
doi 10.3389/fphar.2016.00327
- 4,732 views
- 11 citations
Published in
Frontiers in Pharmacology
Cancer Molecular Targets and Therapeutics
Offline
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore